Autoimmune Hemolytic Anemia (Warm and Cold Agglutinin Disease)

Autoimmune hemolytic anemia (AIHA) is hemolysis caused by autoantibodies directed against the patient's own red blood cells. It is classified by the thermal behavior of the autoantibody into warm AIHA, where IgG antibodies react at body temperature, and cold agglutinin disease, where IgM antibodies agglutinate red cells in colder peripheral conditions and fix complement.

Definition

Autoimmune hemolytic anemia is acquired hemolysis mediated by autoantibodies against red-cell antigens, subclassified by the optimal reaction temperature and immunoglobulin class of the responsible antibody into warm and cold types.

Scope

The entry covers the antibody-based classification of AIHA (warm, cold agglutinin disease, mixed, and paroxysmal cold hemoglobinuria), the role of the direct antiglobulin test in diagnosis, and the distinct mechanisms by which warm and cold antibodies shorten red-cell survival. It is a reference and classification topic and does not provide management or dosing advice. A clinically framed sibling entry exists under immunohematology.

Core questions

• Is the autoantibody warm-reactive (typically IgG) or cold-reactive (typically IgM)?
• What does the direct antiglobulin test pattern (IgG, complement, or both) indicate about mechanism?
• Is the AIHA primary (idiopathic) or secondary to lymphoproliferative disorder, infection, autoimmune disease, or drugs?

Key concepts

• Warm autoimmune hemolytic anemia
• Cold agglutinin disease
• Direct antiglobulin (Coombs) test
• IgG versus IgM autoantibodies
• Complement activation
• Extravascular versus intravascular destruction
• Secondary AIHA
• Paroxysmal cold hemoglobinuria

Mechanisms

In warm AIHA, IgG autoantibodies bind red cells at body temperature; the antibody-coated cells are recognized by Fc receptors of splenic macrophages and removed by extravascular hemolysis, sometimes producing spherocytes (go-2017). In cold agglutinin disease, IgM autoantibodies agglutinate red cells in the cooler peripheral circulation and activate complement, leading to complement-mediated clearance in the liver and, when activation is strong, intravascular hemolysis (berentsen-2021, berentsen-2016). The direct antiglobulin test detects IgG and/or complement (C3) on the red-cell surface and is the central laboratory discriminator between warm and cold disease (jager-2020). The accompanying hemolytic markers — raised LDH and unconjugated bilirubin with low haptoglobin — confirm active destruction (barcellini-2015).

Clinical relevance

Distinguishing warm AIHA from cold agglutinin disease has reference importance because the antibody type defines the mechanism of destruction and the expected laboratory pattern. This entry describes that classification and pathophysiology for educational purposes and is not a basis for individual diagnosis or treatment.

Epidemiology

AIHA is uncommon; warm-antibody disease accounts for the majority of cases, while cold agglutinin disease is rarer and is frequently associated with an underlying clonal B-cell lymphoproliferative process (berentsen-2016). Secondary AIHA may complicate lymphoproliferative disorders, infections, and systemic autoimmune disease (jager-2020).

Evidence & guidelines

The First International Consensus Meeting produced recommendations for the diagnosis and treatment of AIHA in adults (jager-2020); narrative syntheses describe practical diagnostic and pathophysiologic reasoning for warm AIHA (go-2017) and cold agglutinin disease (berentsen-2021, berentsen-2016). These are descriptive references, not prescriptive protocols.

Seminal works

• jager-2020
• go-2017
• berentsen-2021

Frequently asked questions

How do warm and cold autoimmune hemolytic anemia differ?

Warm AIHA is driven by IgG antibodies reacting at body temperature and causing mainly extravascular destruction in the spleen, whereas cold agglutinin disease is driven by IgM antibodies that agglutinate red cells in cooler conditions and activate complement.

What laboratory test confirms an immune cause of hemolysis?

The direct antiglobulin (Coombs) test detects IgG and/or complement on the red-cell surface; its pattern of positivity helps classify the AIHA as warm, cold, or mixed.